Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Sfmg LLC

Sfmg LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 14.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,721 shares of the pharmaceutical company’s stock after purchasing an additional 982 shares during the quarter. Sfmg LLC’s holdings in Vertex Pharmaceuticals were worth $3,142,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of VRTX. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals in the third quarter valued at $25,000. Arlington Trust Co LLC lifted its stake in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares during the last quarter. Compass Wealth Management LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter worth $29,000. Fortitude Family Office LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Finally, Baystate Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VRTX. Robert W. Baird downgraded Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a research note on Wednesday, January 31st. HC Wainwright boosted their target price on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Wolfe Research assumed coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, February 15th. They set an “outperform” rating and a $515.00 price target on the stock. Truist Financial raised their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price on the stock in a research report on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $424.62.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the transaction, the chairman now owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The disclosure for this sale can be found here. Insiders have sold 12,381 shares of company stock valued at $5,203,249 over the last three months. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Trading Down 0.1 %

Shares of VRTX traded down $0.23 on Wednesday, hitting $393.94. 250,366 shares of the stock traded hands, compared to its average volume of 1,240,388. The firm has a market capitalization of $101.82 billion, a P/E ratio of 28.38, a P/E/G ratio of 1.87 and a beta of 0.35. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 1 year low of $316.43 and a 1 year high of $448.40. The stock’s 50 day moving average is $415.28 and its two-hundred day moving average is $396.78.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the firm earned $3.33 earnings per share. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.